- Build a diverse project portfolio with two vaccine candidates based on each of 4 platform technologies
- Accelerate vaccine program development while maintaining safety, efficacy, quality
- Heavy up-front investment
- Partnership of NIAID, Coronavirus Prevention Network, OWS, and sponsor companies

University of California, Davis

- Initiative
- Candidate requirements
- Strategy

Operation Warp Speed

Moncef Slaoui, Ph.D., and Matthew Hepburn, M.D. August 26, 2020 DOI: 10.1056/NEJMp2027405

Developing Safe and Effective Covid Vaccines — Operation Warp Speed’s Strategy and Approach

- Initiative objectives: deliver tens of millions of efficacious and safe COVID-19 vaccines approved/authorized by the FDA for the U.S. population by end of 2020 and/or early 2021.

Initiative

OWS chose candidates based on the following criteria:
- Robust preclinical data or early-stage clinical trial data to support their potential
- Potential (with support from OWS) to enter large phase 3 field efficacy trials July-November 2020
- Deliver outcomes by end of 2020 or first half of 2021
- Candidates had to be based on vaccine-platform technologies permitting fast/effective manufacturing and large-scale abilities
- Use one of four vaccine-platform technologies: mRNA, replication-defective live-vector, recombinant-subunit-adjuvanted protein, attenuated replicating live-vector

Learn Before

Related